EDS

EDS
Name	Ehlers–Danlos syndromes
Field	Dermatology, Medical genetics
Symptoms	hyperextensible skin; joint hypermobility; tissue fragility
Complications	arterial rupture; organ rupture; chronic pain; osteoarthritis
Onset	congenital or early life
Duration	lifelong
Causes	pathogenic variants in collagen-related genes
Diagnosis	clinical evaluation; genetic testing; skin biopsy
Treatment	multidisciplinary management; surgery; physical therapy
Frequency	variable by subtype

EDS

Ehlers–Danlos syndromes are a heterogeneous group of heritable connective tissue disorders characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. Presentations range from predominantly cutaneous manifestations to life-threatening vascular complications; clinical care often involves Johns Hopkins Hospital, Mayo Clinic, Great Ormond Street Hospital, and specialty clinics in Boston, London, and Paris. Research into molecular mechanisms has involved institutions such as National Institutes of Health, Karolinska Institute, Harvard Medical School, University of Cambridge, and Stanford University.

Ehlers–Danlos syndromes

The syndromes are classified into distinct subtypes based on clinical criteria and genetic etiology, including classical, hypermobile, vascular, kyphoscoliotic, arthrochalasia, dermatosparaxis, and several rarer forms described in consensus documents from Villefranche (2000), International EDS Consortium, and the 2017 international classification endorsed by World Health Organization collaborators. Notable genes implicated include COL5A1, COL5A2, COL3A1, TNXB, PLOD1, FKBP14, ADAMTS2, and SLC39A13; pathogenic variants were reported by groups at National Human Genome Research Institute, Wellcome Sanger Institute, and European Molecular Biology Laboratory. Clinical overlap with disorders treated at Boston Children’s Hospital, Cleveland Clinic, Sheffield Children’s Hospital, and other centers complicates diagnosis and referral patterns.

Signs and symptoms

Common manifestations comprise skin hyperextensibility, atrophic scarring, fragile tissues, and generalized joint hypermobility leading to recurrent dislocations and chronic pain; symptomatic burden often necessitates care from American Pain Society, European Society of Cardiology, British Pain Society, and multidisciplinary teams at tertiary centers like Mayo Clinic. Vascular subtype can present with arterial dissection or rupture, organ rupture, or uterine rupture relevant to care guidelines from Society for Vascular Surgery and obstetric units at Guy’s and St Thomas’ NHS Foundation Trust and Royal Women’s Hospital. Musculoskeletal complications include early-onset osteoarthritis managed in programs at Hospital for Special Surgery and Rothman Orthopaedics; autonomic dysfunction and dysautonomia intersect with services at Cleveland Clinic Autonomic Disorders Program. Neurocognitive and psychiatric comorbidities engage specialists from Massachusetts General Hospital and UCLA Health.

Genetics and pathophysiology

Pathogenesis involves defects in fibrillar collagen biosynthesis, cross-linking, extracellular matrix assembly, and tenascin or proteoglycan interactions; foundational biochemical work was conducted at Max Planck Institute, Institut Pasteur, and University of Oxford. COL3A1 glycine substitutions underlie vascular fragility described in case series from Vascular Society centers; COL5A1/COL5A2 haploinsufficiency explains classical phenotypes reported by investigators at Johns Hopkins School of Medicine. Enzymatic defects such as PLOD1 deficiency cause kyphoscoliotic presentations studied at Charité – Universitätsmedizin Berlin and Erasmus MC. Cell biology studies at Cold Spring Harbor Laboratory and Weizmann Institute of Science illuminate altered mechanotransduction and matrix remodeling leading to clinical features observed in cohorts at UCL Great Ormond Street Institute of Child Health.

Diagnosis

Diagnostic strategies combine clinical criteria from international consortia with molecular testing via targeted gene panels, whole-exome sequencing, and copy-number analysis performed by laboratories at Mayo Clinic Laboratories, ARUP Laboratories, and GeneDx. Skin biopsy with electron microscopy and biochemical collagen analysis remains informative in select subtypes; pathology services at John Radcliffe Hospital and Institut Clinique de la Souris have contributed case series. Differential diagnosis includes disorders managed at Royal National Orthopaedic Hospital and genetic syndromes cataloged by Online Mendelian Inheritance in Man and databases curated by European Society of Human Genetics. Clinical diagnostic criteria are periodically updated by working groups convened by International Consortium on Ehlers–Danlos Syndromes and published in journals associated with American College of Medical Genetics.

Management and treatment

There is no cure; management emphasizes prevention of complications, symptomatic relief, and rehabilitation coordinated by teams at Mayo Clinic, Boston Children’s Hospital, Great Ormond Street Hospital, and specialized centers in Sydney and Toronto. Interventions include physiotherapy protocols developed at University of Sydney, pain management from programs at Johns Hopkins Pain Center, orthopedic surgery at Hospital for Special Surgery, vascular surgery guidance from Society for Vascular Surgery, and obstetric planning involving Royal College of Obstetricians and Gynaecologists. Pharmacologic strategies may involve analgesics, antihypertensives for vascular protection as recommended by European Society of Cardiology, and targeted perioperative precautions described by anesthesiology teams at Massachusetts General Hospital. Patient advocacy and support are provided by organizations such as Ehlers-Danlos Society, Genetic and Rare Diseases Information Center, and registries affiliated with NIH Clinical Center.

Epidemiology

Prevalence varies by subtype: classical and hypermobile forms are relatively common in referral cohorts reported by University of Washington, King’s College London, and St Thomas’ Hospital, while vascular and dermatosparaxis types are rare with population estimates derived from studies at Swedish National Board of Health and Welfare and national registries coordinated by European Reference Networks. Epidemiologic research has been conducted using data from UK Biobank, All of Us Research Program, and national health databases in Denmark and Finland.

History and society

Historical descriptions trace back to 19th-century clinicians; eponymous reports were advanced by researchers in Germany, Austria-Hungary, and later consolidated in 20th-century texts from Guy’s Hospital Medical School and Johns Hopkins Hospital. Contemporary social and policy issues involve access to multidisciplinary care, disability recognition, and research funding advocated by groups such as National Organization for Rare Disorders, European Commission initiatives on rare diseases, and patient-led campaigns in Australia and Canada. Notable scientific contributors and clinical centers include investigators at Harvard Medical School, University of Cambridge, Karolinska Institute, and patient registries coordinated through NIH.

Category:Genetic disorders